Nepafenaco para edema macular cistoideo secundario a paclitaxel

  1. H.E. Tapia Quijada 2
  2. E. Quijada Fumero 12
  3. F.I. Mesa Lugo 2
  4. M. Serrano García 12
  5. N. Betancor Caro 12
  1. 1 Centro de Enfermedades Oculares Serrano, Tenerife, España
  2. 2 Hospital Universitario de Canarias
    info

    Hospital Universitario de Canarias

    San Cristóbal de La Laguna, España

    ROR https://ror.org/05qndj312

Revue:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Année de publication: 2021

Volumen: 96

Número: 8

Pages: 434-437

Type: Article

DOI: 10.1016/J.OFTAL.2020.10.014 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Archivos de la Sociedad Española de Oftalmologia

Objectifs de Développement Durable

Résumé

Paclitaxel is used to treat a wide range of malignant tumours. This type of drug is known to cause ocular adverse effects, with cystoid macular oedema being a known, but rare complication, of this therapy. Although most cases resolve after discontinuation of the drug, several authors have attempted various treatments to accelerate resolution, or when paclitaxel therapy cannot be discontinued. A case is presented of a 62 year-old man who presented with decreased visual acuity due to bilateral cystoid macular oedema after administration of paclitaxel for oesophageal cancer. As part of the study, optical coherence tomography angiography (OCTA) was performed at the time of diagnosis, and later when the symptoms subsided. Nepafenac eye drops were prescribed as treatment.

La source de données: Dialnet